ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

University Hospitals Leuven at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

University Hospitals Leuven takes part in 11 sessions at ESMO 2026 in Madrid. Its work spans gastrointestinal, breast, genitourinary and gynaecological cancers, including biomarker-guided treatment. Specific topics include targeted therapies in upper digestive cancers and antibody-based treatments for gynaecological cancers.

OrganizationESMO 2026 Attendance
Cancer centre & hospital
Teaching hospital group of KU Leuven in Leuven, Belgium, with its main campus at Gasthuisberg.
Poster
Fri Oct 23
13:00–15:00
Abstract
Fri Oct 23
14:42–14:52
Invited Discussant LBA82 and LBA83
Proffered paper 1: Gastrointestinal tumour, upper digestive
Gastrointestinal cancers
Chair
Sat Oct 24
08:30–10:00
Rapid oral 2: Gynaecological cancers
with Evangelische Kliniken Essen-Mitte, Policlinico Universitario Agostino Gemelli
Gynaecological cancers
Abstract
Sat Oct 24
09:24–09:36
Invited Discussant 1246RO and 1247RO
Rapid oral 2: Gynaecological cancers
Gynaecological cancers
Satellite
Sun Oct 25
19:25–19:45
Future Directions: Next‑Generation ADCs and Emerging Targets for Platinum-resistant
Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions
Breast cancerGynaecological cancers
Satellite
Sun Oct 25
19:45–20:00
Connecting Experience, Potential, and Future Frontiers: Panel discussion and audience Q&A
Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions · with Latin American Cooperative Oncology Group, University of California San Diego
Breast cancerGynaecological cancers
Chair
Mon Oct 26
08:30–10:00
Navigating the wave of new therapies in gynaecologic cancers
with Gustave Roussy
Gynaecological cancers
Talk
Mon Oct 26
09:00–09:15
Overview of RAS and other mutational targets
Advancing targeted and immunotherapeutic strategies in upper GI cancer
Gastrointestinal cancers
Talk
Mon Oct 26
09:10–09:30
Present and future of ADC in gynaecological cancers
Navigating the wave of new therapies in gynaecologic cancers
Gynaecological cancers
Talk
Mon Oct 26
14:45–14:50
Presentation of case/condition
Optimal multidisciplinary management of penile cancer
Genitourinary cancers
Talk
Mon Oct 26
14:50–15:10
The surgical oncology point of view: Role of surgery of primary and LN
Optimal multidisciplinary management of penile cancer
Genitourinary cancers
Satellite
Mon Oct 26
19:00–19:20
How I Test, How I Think, How I Treat: Clinical Evidence, Best Practices, and Hot Seat Challenges, Part 2: The Past, Present, and Future Role of HER2-Targeting ADCs Across
PeerView Oncology - Leveraging HER2-Targeted ADCs in Solid Tumours: Expert Strategies for Advancing Biomarker Testing, Decoding Data, and Closing Treatment Gaps
Biomarkers & precision oncology
Satellite
Mon Oct 26
19:40–20:00
Open Discussion Forum, Q&A and Key Takeaways: Optimizing Treatment With HER2- Directed ADCs to Close Treatment Gaps in Solid Tumours
PeerView Oncology - Leveraging HER2-Targeted ADCs in Solid Tumours: Expert Strategies for Advancing Biomarker Testing, Decoding Data, and Closing Treatment Gaps · with Fred & Pamela Buffett Cancer Center, National Cancer Centre Singapore
Biomarkers & precision oncology

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at University Hospitals Leuven

Tell us what you sell and we’ll find the people at University Hospitals Leuven most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction